PCL, Inc. (KOSDAQ:241820)

Market Cap	17.87B
Revenue (ttm)	4.98B -36.8%
Net Income	-47.06B
EPS	-14,020.37
Shares Out	2.96M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	237,458
Average Volume	45,771
Open	307.00
Previous Close	307.00
Day's Range	300.00 - 307.00
52-Week Range	300.00 - 43,800.00
Beta	1.70
RSI	24.19
Earnings Date	Mar 20, 2026

About PCL, Inc.

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers HiSU solution, an automated multi-immune diagnostic system that performs various diagnostics, high-speed tests including blood screening, multiple cancer screening, autoimmune testing, etc. It also provides antigen and antibody diagnostic kits, including PCLOK II anti-HIV/HCV/syphilis, and PCLOK II HBsAg/HIV p24. In addition, the company offers platform services, such as SG ID for identifying novel target substances. Further, it offers covi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2008
• Employees: 31
• Stock Exchange: KOSDAQ
• Ticker Symbol: 241820

Financial Performance

In 2024, PCL, Inc.'s revenue was 1.25 billion, a decrease of -85.22% compared to the previous year's 8.43 billion. Losses were -52.34 billion, 157.6% more than in 2023.